The potential role of Bi-specific antibodies in acute myeloid leukemia

被引：4
|
作者：
Yilmaz, Musa [1 ]
Ravandi, Farhad [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1400 Holcombe Blvd,Unit 428, Houston, TX 77030 USA
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2020年 / 33卷 / 04期
关键词：
Bispecific antibody; BiTE; DART; BiKE; TriKE; Tandem antibody; AML; Immunotherapy; T-CELL ENGAGER; RECEPTOR-ALPHA CHAIN; STEM-CELL; MACROPHAGE ACTIVATION; MONOCLONAL-ANTIBODY; AMG; 330; TARGET; EXPRESSION; CD123; CD33;
D O I：
10.1016/j.beha.2020.101218
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bispecific antibodies consist of antigen recognition sites from two or more antibodies redirecting effector immune cell against target on tumor cells. Rapidly evolving medical technologies enabled engineering and development of recombinant protein products, and this, combined with interest from the pharmaceutical industry, further advanced the bispecific antibody research. Over 50 different types of bispecific antibody constructs are now being manufactured and explored in ongoing or future clinical trials. In this review, we will summarize the available data for bispecific antibodies developed and being investigated for the treatment of patients with acute myeloid leukemia.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] PRODUCTION OF BI-SPECIFIC MONOCLONAL-ANTIBODIES IN A HOLLOW-FIBER BIOREACTOR
    GORTER, A
    VANDEGRIEND, RJ
    VANEENDENBURG, JDH
    HAASNOOT, WHB
    FLEUREN, GJ
    JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 161 (02) : 145 - 150
  • [22] New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement
    Goubran, Hadi
    Goubran, Mariam
    Seghatchian, Jerard
    Burnouf, Thierry
    TRANSFUSION AND APHERESIS SCIENCE, 2019, 58 (02) : 208 - 211
  • [23] Monoclonal antibodies for the treatment of acute myeloid leukemia
    Abutalib, Syed A.
    Tallman, Martin S.
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, 7 (05) : 343 - 369
  • [24] Monoclonal antibodies and immunoconjugates in acute myeloid leukemia
    Amadori, Sergio
    Stasi, Roberto
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 715 - 736
  • [25] Acute myeloid leukemia targets for bispecific antibodies
    Hoseini, S. S.
    Cheung, N. K.
    BLOOD CANCER JOURNAL, 2017, 7 : e522 - e522
  • [26] Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
    Guy, Daniel G.
    Uy, Geoffrey L.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 417 - 425
  • [27] Acute myeloid leukemia targets for bispecific antibodies
    S S Hoseini
    N K Cheung
    Blood Cancer Journal, 2017, 7 : e522 - e522
  • [28] Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
    Daniel G. Guy
    Geoffrey L. Uy
    Current Hematologic Malignancy Reports, 2018, 13 : 417 - 425
  • [29] Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia
    Faderl, Stefan
    Gandhi, Varsha
    Kantarjian, Hagop M.
    CURRENT OPINION IN HEMATOLOGY, 2008, 15 (02) : 101 - 107
  • [30] VALIDATION OF BI-SPECIFIC T-CELL ENGAGER (BITE®) ANTIBODY ACTIVITY IN VITRO AND IN VIVO AGAINST DIFFERENTIALLY EXPRESSED CELL SURFACE TARGETS IN ACUTE MYELOID LEUKEMIA
    Sinclair, A. M.
    Nazarian, A. A.
    Homann, O.
    Zhang, S.
    Archibeque, I.
    Busse, L.
    Koppikar, P.
    Hale, K.
    Newhall, K.
    Powers, D.
    Foltz, I.
    Moriguchi, J.
    McElroy, T.
    Manchulenko, K.
    Moody, G.
    Bakker, A.
    HAEMATOLOGICA, 2014, 99 : 293 - 294
12345